OBJECTIVE: This study examined the effects of adjunctive aripiprazole therapy on metabolism in clozapine-treated patients with schizophrenia. METHOD: In an 8-week randomized, double-blind, placebo-controlled study, subjects received either aripiprazole (15 mg/day) or placebo. At baseline and week 8, metabolic parameters were assessed by the frequently sampled intravenous glucose tolerance test, nuclear magnetic resonance spectroscopy and whole-body dual-energy X-ray absorptiometry (DXA). RESULTS:Thirty subjects completed the study (16 in the aripiprazole group and 14 in the placebo group). Glucose effectiveness measured by the frequently sampled intravenous glucose tolerance test improved significantly in the aripiprazole group (0.003 ± 0.006 vs. -0.005 ± 0.007/min, P = 0.010). The aripiprazole group showed significant reductions in both plasma low-density lipoprotein (LDL) levels (-15.1 ± 19.8 vs. 4.4 ± 22.5 mg/dl, P = 0.019) and LDL particle numbers (-376 ± 632 vs. -36 ± 301 nm, P = 0.035). Further, there was a significant reduction in the lean mass (-1125 ± 1620 vs. 607 ± 1578 g, P = 0.011) measured by whole-body DXA scan in the aripiprazole group. All values were expressed as mean ± standard deviation, aripiprazole vs. placebo. CONCLUSION: Adjunctive therapy with aripiprazole may have some metabolic benefits in clozapine-treated patients with schizophrenia.
RCT Entities:
OBJECTIVE: This study examined the effects of adjunctive aripiprazole therapy on metabolism in clozapine-treated patients with schizophrenia. METHOD: In an 8-week randomized, double-blind, placebo-controlled study, subjects received either aripiprazole (15 mg/day) or placebo. At baseline and week 8, metabolic parameters were assessed by the frequently sampled intravenous glucose tolerance test, nuclear magnetic resonance spectroscopy and whole-body dual-energy X-ray absorptiometry (DXA). RESULTS: Thirty subjects completed the study (16 in the aripiprazole group and 14 in the placebo group). Glucose effectiveness measured by the frequently sampled intravenous glucose tolerance test improved significantly in the aripiprazole group (0.003 ± 0.006 vs. -0.005 ± 0.007/min, P = 0.010). The aripiprazole group showed significant reductions in both plasma low-density lipoprotein (LDL) levels (-15.1 ± 19.8 vs. 4.4 ± 22.5 mg/dl, P = 0.019) and LDL particle numbers (-376 ± 632 vs. -36 ± 301 nm, P = 0.035). Further, there was a significant reduction in the lean mass (-1125 ± 1620 vs. 607 ± 1578 g, P = 0.011) measured by whole-body DXA scan in the aripiprazole group. All values were expressed as mean ± standard deviation, aripiprazole vs. placebo. CONCLUSION: Adjunctive therapy with aripiprazole may have some metabolic benefits in clozapine-treated patients with schizophrenia.
Authors: D C Henderson; L Kunkel; D D Nguyen; C P Borba; T B Daley; P M Louie; O Freudenreich; C Cather; A E Evins; D C Goff Journal: Acta Psychiatr Scand Date: 2006-02 Impact factor: 6.392
Authors: David C Henderson; Dana D Nguyen; Paul M Copeland; Doug L Hayden; Christina P Borba; Pearl M Louie; Oliver Freudenreich; A Eden Evins; Corrine Cather; Donald C Goff Journal: J Clin Psychiatry Date: 2005-09 Impact factor: 4.384
Authors: Jean Y Zhang; Dianne M Kowal; Stanley P Nawoschik; Zhuangwei Lou; John Dunlop Journal: Biochem Pharmacol Date: 2005-12-05 Impact factor: 5.858
Authors: David C Henderson; Enrico Cagliero; Paul M Copeland; Christina P Borba; Anne Eden Evins; Doug Hayden; Mary T Weber; Ellen J Anderson; David B Allison; Tara B Daley; David Schoenfeld; Donald C Goff Journal: Arch Gen Psychiatry Date: 2005-01
Authors: Robert D McQuade; Elyse Stock; Ron Marcus; Darlene Jody; Neveen A Gharbia; Simon Vanveggel; Don Archibald; William H Carson Journal: J Clin Psychiatry Date: 2004 Impact factor: 4.384
Authors: Prakash S Masand; Larry Culpepper; David Henderson; Scott Lee; Kimberly Littrell; John W Newcomer; Natalie Rasgon Journal: CNS Spectr Date: 2005-10 Impact factor: 3.790
Authors: Donald C Goff; Corinne Cather; A Eden Evins; David C Henderson; Oliver Freudenreich; Paul M Copeland; Michael Bierer; Kenneth Duckworth; Frank M Sacks Journal: J Clin Psychiatry Date: 2005-02 Impact factor: 4.384
Authors: Joseph P McEvoy; Jeffrey A Lieberman; T Scott Stroup; Sonia M Davis; Herbert Y Meltzer; Robert A Rosenheck; Marvin S Swartz; Diana O Perkins; Richard S E Keefe; Clarence E Davis; Joanne Severe; John K Hsiao Journal: Am J Psychiatry Date: 2006-04 Impact factor: 19.242
Authors: Sri Mahavir Agarwal; Nicolette Stogios; Zohra A Ahsan; Jonathan T Lockwood; Markus J Duncan; Hiroyoshi Takeuchi; Tony Cohn; Valerie H Taylor; Gary Remington; Guy E J Faulkner; Margaret Hahn Journal: Cochrane Database Syst Rev Date: 2022-10-03
Authors: Brenda Vincenzi; Claire M Greene; Melissa Ulloa; Lindsey Parnarouskis; John W Jackson; David C Henderson Journal: J Psychiatr Pract Date: 2016-05 Impact factor: 1.325
Authors: Louise Benarroch; Chantel Kowalchuk; Virginia Wilson; Celine Teo; Melanie Guenette; Araba Chintoh; Yasika Nesarajah; Valerie Taylor; Peter Selby; Paul Fletcher; Gary J Remington; Margaret K Hahn Journal: Psychopharmacology (Berl) Date: 2016-06-01 Impact factor: 4.530
Authors: Deanna L Kelly; Heidi J Wehring; Amber K Earl; Kelli M Sullivan; Faith B Dickerson; Stephanie Feldman; Robert P McMahon; Robert W Buchanan; Dale Warfel; William R Keller; Bernard A Fischer; Joo-Cheol Shim Journal: BMC Psychiatry Date: 2013-08-22 Impact factor: 3.630